Native Labs Secures Funding to Boost Biopharma Innovation
Revolutionizing Biopharma: How Native Labs is Attracting Investment to Transform Cell and Gene Therapies
At the cutting edge of AI, biology, and robotics, Native Labs stands poised to tackle the significant manufacturing bottlenecks frustrating the rapid deployment of life-saving cell and gene therapies. Founded by Louis Brookstein and Arya Shabani, this innovative startup blends robust industrial expertise with their academic backgrounds to identify and address the intricate challenges that biopharma customers face. Their vision goes beyond mere problem-solving; it's a mission to revolutionize the biopharma landscape by creating state-of-the-art solutions that enhance communication between therapy developers and manufacturers, ultimately transforming the patient experience.
Recently, Native Labs secured a pivotal funding round led by Zinc VC, which is set to supercharge the deployment of its advanced AI platform across manufacturing sites and process development labs. This comes on the heels of the company’s previous achievements, including winning an Innovate UK grant and gaining a year of complimentary lab space at the Stevenage Bioscience Catalyst. As Emilie Syed from Zinc VC noted, “Their platform is addressing one of the most challenging bottlenecks in the field,” which underscores the enormous potential Native Labs holds in a rapidly growing market poised to redefine patient outcomes.
Looking ahead, Native Labs is on a trajectory to not only refine its offerings but also expand its partnerships within the biopharma ecosystem. The recent round of funding allows them to double down on their commitment to overcoming the most pressing challenges in the industry. CEO Louis Brookstein expressed gratitude towards Zinc VC and emphasized the flexibility of their AI architecture that enables swift iterations and feature development. With plans to invite beta testers for their groundbreaking platform, Native Labs is signaling a call to investors and partners interested in unlocking the value of historical datasets to co-create tailored AI solutions—ushering in a new era of transformative investment in the biopharmaceutical realm.
Key Terms Explained
- AI (Artificial Intelligence)
- AI typically refers to the simulation of human intelligence in machines that are programmed to think like humans and mimic their actions. This can also refer to the innovation of creating machines that can solve complex problems indigenously.
- Pivotal Funding Round
- This refers to an important stage in the venture capital financing of a startup, used for further growth. This is typically a significant amount of money that can help the startup to reach the next phase of its development.
- Zinc VC
- This represents a venture capital firm. Venture capitalists provide funding to startups they believe have long-term growth potential. This type of investment typically involves a higher risk but promises a higher return if the startup succeeds.
Frequently Asked Questions
- Who are the founders of Native Labs?-Native Labs was founded by Louis Brookstein and Arya Shabani.
- What is the mission of Native Labs in the biopharma landscape?+
- Which investment firm led the recent funding round for Native Labs?+
- What impact will the funding have on Native Labs?+
- What is Native Labs planning with regards to their AI platform?+
They've invested in Native Labs
Get to know these AI investors
Click here for a full list of 6,908+ startup investors in the UK